engage checkpoint medical linkedin twitter

Podcast: Advanced HCC Highlights from ILCA and ESMO 2022

Podcast: Advanced HCC Highlights from ILCA and ESMO 2022

Assoc. Prof. Matthias Pinter, Prof. Dr. Jeroen Dekervel

In this podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented at the ILCA and ESMO congresses, 2022. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.




Portrait of Matthias Pinter
Assoc. Prof. Matthias Pinter


Medical University of Vienna


Jeroen Dekervel
Prof. Dr. Jeroen Dekervel

GI Oncologist

UZ Leuven


preview next

Podcast: Advanced HCC Highlights from ILCA and ESMO 2022

time | open 30 min | Oct 2022

Subscribe to our podcast series on:

download resources

I agree that this educational programme:

This educational programme is supported by an Independent Medical Education Grant from Bayer

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.

Other programmes of interest

preview next